Dr. Goldfarb’s research interests span the field of cancer, including metastasis, tumor invasion, anti-cancer drug discovery, angiogenesis, and immune effector mechanisms. He has been a leader in the development of animal models that are widely used for cancer research, as well as their use in oncology drug discovery and development programs. Prior to joining Sopherion, Dr. Goldfarb was the Chairman of the Department of Molecular Biology and Immunology and Director of the Institute for Cancer Research at the University of North Texas Heath Science Center at Fort Worth, Texas. Prior to his position in Texas, he was the Deputy Director of the University of Pittsburgh Cancer Institute (UPCI), an NCI, NIH-designated Comprehensive Cancer Center, where he had responsibility for basic and translational research. Earlier, he served as Associate Director for Basic Research and as Director of the Programs in Experimental Therapeutics and Cancer Metastasis and Cell Biology, at UPCI.

Dr. Goldfarb was also Professor of Pathology and Neurosurgery at the University of Pittsburgh School of Medicine and on the Board of the Ben Franklin Technology Center of Western Pennsylvania. Earlier in his career, Dr. Goldfarb led an oncology drug discovery effort at Pfizer. Dr. Goldfarb has chaired and participated in multiple federal and state peer-review panels to evaluate research proposals, including the NIH, Department of Defense, and the University of California. Throughout his career, Dr. Goldfarb has served on the Scientific Advisory Boards of four biotechnology companies. He has published over 135 full papers, has edited/co-edited five volumes in areas of cancer, tumor immunology, and cancer therapy, has served as Associate Editor of two journals and participated in the Editorial Board of three journals.

Dr. Goldfarb holds several US and worldwide patents in anti-cancer drug discovery. Among the many awards bestowed upon him, Dr. Goldfarb received one for Outstanding Service to the Cause of Cancer Control from the American Cancer Society in 2002.